Please ensure Javascript is enabled for purposes of website accessibility


Big things are happening at Ogier. Change is embedded in everything we do. It is redefining our talent, our ways of working, our platforms of delivery, our culture.



We have the expertise to handle the most demanding transactions. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies means we add real value to clients’ businesses.

View all services

Business Services Team

View all Business Services Team


Our sector approach relies on smart collaboration between teams who have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients to see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier advises on US$850m refinancing for leading Chinese nutritional firm


03 August 2016

Save as PDF

Ogier has recently acted as Cayman and BVI counsel to Biostime, a leading Chinese producer of infant nutritional products, enabling it to raise a total of US$850m of new financing as part of a combined capital markets and bank fundraising exercise.

The transaction involved the combination of new US$400m 7.25% high yield notes, due 2021, as well as a US$450m term loan facility and a tender offer for Biostime’s existing HK$3.1bn Convertible Bonds, due 2019.

The loan facility was made available in a single instalment, the proceeds of which were used to refinance a US$450m acquisition bridge loan that was initially incurred for the acquisition of its 83% shareholding in Swisse, one of Australia’s leading vitamin and supplements providers, last September.

The proceeds of the High Yield Notes were placed in a secured escrow account to solely fund the redemption of the Convertible Bonds. The Tender Offer was structured as a modified Dutch auction and was conditional on the successful completion of the High Yield Notes. Approximately US$230m of Convertible Bonds were successfully re-purchased through the Tender Offer.

Hong Kong-based Ogier partner, Anthony Oakes said: “We enjoyed working with Biostime across these combined banking and capital markets transactions.  The transactions were part of a balance sheet management exercise following Biostime’s acquisition of Swisse last year, with our elements reflecting both the sophistication of our cross-border expertise and the appeal of BVI and Cayman structures where Asian institutions are concerned.”

The lead counsel on the transaction were Clifford Chance who acted for Biostime and Linklaters who acted for the lead manager.

No Content Set